Management of Bronchitis
The management of bronchitis depends critically on whether you are treating acute bronchitis (a self-limited viral illness) or chronic bronchitis (a component of COPD), as these require fundamentally different approaches.
Acute Bronchitis Management
For acute uncomplicated bronchitis in immunocompetent adults, antibiotics should NOT be routinely prescribed 1, 2, 3. More than 90% of acute bronchitis cases are viral in origin 2, 4, and antibiotics provide minimal benefit—reducing cough duration by only approximately 0.5 days while exposing patients to unnecessary adverse effects and contributing to antibiotic resistance 3, 5.
Key Management Principles for Acute Bronchitis:
No routine diagnostic testing is indicated unless pneumonia, influenza, COVID-19, or pertussis is suspected 1, 3
Symptomatic treatment only: The evidence does NOT support routine use of antitussives, honey, antihistamines, anticholinergics, oral NSAIDs, or inhaled/oral corticosteroids 1, 3
Patient education is critical: Inform patients that cough typically lasts 2-3 weeks and is self-limiting 3, 4
Antibiotics should only be considered if the condition worsens and a complicating bacterial infection (such as pneumonia) is suspected, or if pertussis is confirmed 1, 2
Important Clinical Pitfall:
Purulent or discolored (green/yellow) sputum does NOT indicate bacterial infection—it reflects inflammatory cells and sloughed epithelial cells, not bacteria 2, 4. This is a common misconception that leads to inappropriate antibiotic prescribing.
Chronic Bronchitis Management
Chronic bronchitis is defined as cough with sputum production for at least 3 months per year during 2 consecutive years, with other causes excluded 6. Management differs substantially based on disease stability versus acute exacerbation.
For STABLE Chronic Bronchitis:
The single most important intervention is avoidance of respiratory irritants, particularly smoking cessation 6, 7, 6.
Bronchodilator Therapy (Grade A Recommendations):
Short-acting β-agonists should be used to control bronchospasm and relieve dyspnea; may also reduce chronic cough in some patients 6
Ipratropium bromide should be offered to improve cough—it reduces cough frequency, severity, and sputum volume 6
Theophylline may be considered for chronic cough control, but requires careful monitoring for complications due to side effects and drug interactions 6
Inhaled Corticosteroids:
- Recommended when FEV1 < 50% and there is a history of frequent exacerbations 6
- Combined long-acting β-agonist plus inhaled corticosteroid reduces exacerbation rates and cough in COPD patients 6
What NOT to Use in Stable Disease:
- No prophylactic antibiotics—not recommended due to antibiotic resistance concerns and lack of benefit 6
- No postural drainage or chest percussion—clinical benefits not proven 6
- No expectorants—beneficial effects not proven 6
- No oral corticosteroids—no evidence of benefit and significant side effects 6
For ACUTE EXACERBATIONS of Chronic Bronchitis:
An acute exacerbation is characterized by increased sputum volume, sputum purulence, and/or worsening dyspnea 6. The Anthonisen criteria (at least 2 of these 3 symptoms) suggest bacterial origin 8.
Treatment Algorithm for Exacerbations:
1. Bronchodilators (Grade A):
- Start with short-acting β-agonists OR anticholinergic bronchodilators 6
- If no prompt response, add the other agent after maximizing the first 6
- Do NOT use theophylline during acute exacerbations (Grade D) 6
2. Antibiotics (Grade A):
- Recommended for acute exacerbations, especially in patients with severe exacerbations or more severe baseline airflow obstruction 6
- Target organisms: S. pneumoniae, H. influenzae, Branhamella catarrhalis 8
- Most beneficial in patients with FEV1 < 35% or chronic respiratory insufficiency 8
3. Systemic Corticosteroids (Grade A):
- A short course (10-15 days) should be given for acute exacerbations 6
- IV therapy for hospitalized patients; oral therapy for ambulatory patients 6
- A 2-week course is equivalent to 8 weeks with fewer side effects 6
4. What NOT to Use:
- No expectorants—no evidence of effectiveness 6
- No postural drainage or chest percussion—not proven beneficial 6
- No mucokinetic agents—not useful during exacerbations 6
Critical Distinction for Clinical Practice:
The term "bronchitis" without qualification is ambiguous. Always clarify whether you are managing:
- Acute bronchitis = viral illness requiring only symptomatic care and patient education
- Chronic bronchitis = COPD-spectrum disease requiring bronchodilators ± inhaled corticosteroids
- Acute exacerbation of chronic bronchitis = requires bronchodilators + antibiotics + systemic corticosteroids
This distinction is essential because antibiotics are harmful (through unnecessary side effects and resistance) in acute bronchitis but beneficial in exacerbations of chronic bronchitis 6, 1, 2.